A new biomarker derived from the Framingham Heart Study measures the speed of biological decline, offering a more sensitive endpoint for anti-aging clinical trials. A rate-based biomarker from the Fra...
Plasma p-tau217 can predict Alzheimer’s decades early, but lack of protocols raises ethical concerns. Lifestyle interventions may bridge the gap. A blood test can now forecast Alzheimer’s ...
Despite validated p-tau217 blood tests for early Alzheimer’s prediction, clinical adoption lags due to lack of interventions and standardized protocols. Blood biomarker p-tau217 can predict Alzh...
7-ketocholesterol (7KC), an oxidized cholesterol, is linked to cardiovascular and neurodegenerative diseases, with recent AI diagnostics and clinical trials advancing preventive healthcare for aging p...
A new blood test based on p-tau217 biomarker can predict Alzheimer’s symptom onset in 3-4 years with high accuracy, offering early intervention opportunities. Recent studies validate a p-tau217 ...